Bio-Techne (TECH) 10-K/A risk factor changes: FY2026 vs FY2019
The 2026-06-30 10-K/A against the 2019-06-30 one, compared heading by heading and sentence by sentence. One of these filings carries no fiscal year tag, so its year is the calendar year of the period end.
All filing items27 rewritten871 added1,301 removed17 unchanged
Summary
counted, not written
- Item 1A headings could not be compared: the parser did not find an Item 1A in both filings.
- Sentence by sentence, 871 added, 1,301 removed, 27 rewritten and 17 unchanged across 7 items that differ.
- New this year: Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS; Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.
- Not in this year's filing: Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA; Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE; Item 9A. CONTROLS AND PROCEDURES; Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.
Sentences by item
7 items, with every count and a link to each item that changed
| Item | Added | Removed | Rewritten | Unchanged | Page headers and footers changed |
|---|---|---|---|---|---|
| Cover and table of contents | 755 | 13 | 27 | 17 | 0 |
| Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERSnew | 65 | 0 | 0 | 0 | 0 |
| Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCEnew | 51 | 0 | 0 | 0 | 0 |
| Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATAdropped | 0 | 1,181 | 0 | 0 | 0 |
| Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSUREdropped | 0 | 1 | 0 | 0 | 0 |
| Item 9A. CONTROLS AND PROCEDURESdropped | 0 | 29 | 0 | 0 | 0 |
| Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULESdropped | 0 | 77 | 0 | 0 | 0 |
Underlined words on a shaded ground are new in FY2026; struck-through words were in FY2019. Sentences that are wholly new or wholly gone are labelled rather than marked.
Cover and table of contents
27 rewritten, 755 added, 13 removed, 17 unchanged
Read the full itemFY2026 item · filed October 28, 2026FY2019 item · filed October 9, 2019
[removed: UNITED STATES][added: UNITED STATES]
[removed: SECURITIES] [added: SECURITIES] AND EXCHANGE [removed: COMMISSION][added: COMMISSION]
[removed: Washington,] [added: Washington,] DC [removed: 20549][added: 20549]
[removed: FORM 10-K][added: FORM 10-K/A]
[removed: Amendment] [added: (Amendment] No. [removed: 1][added: 1)]
| ☒ | [removed: ANNUAL] [added: ANNUAL] REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF [removed: 1934] [added: 1934] |
[removed: For] [added: For] the fiscal year ended June 30, [removed: 2019, or][added: 2026, or]
| ☐ | [removed: TRANSITION] [added: TRANSITION] REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF [removed: 1934] [added: 1934] |
[removed: For] [added: For] the transition [removed: period][added: period]
[removed: Commission] [added: Commission] file number [removed: 0-17272][added: 0-17272]
[removed: BIO-TECHNE CORPORATION][added: BIO-TECHNE CORPORATION]
[removed: (Exact] [added: (Exact] name of registrant as specified in its [removed: charter)][added: charter)]
| [removed: Minnesota] [added: Minnesota] | | [removed: 41-1427402] [added: 41-1427402] |
| [removed: (State] [added: (State] or other jurisdiction [removed: of incorporation] [added: of incorporation] or [removed: organization)] [added: organization)] | | [removed: (I.R.S. Employer Identification No.)] [added: (I.R.S. Employer Identification No.)] |
| [removed: 614] [added: 614] McKinley Place [removed: N.E. Minneapolis,] [added: N.E. Minneapolis,] MN [removed: 55413] [added: 55413] | | [removed: (612) 379-8854] [added: (612) 379-8854] |
| [removed: (Address] [added: (Address] of principal executive offices) (Zip [removed: Code)] [added: Code)] | | [removed: (Registrant's] [added: (Registrant’s] telephone number, including area [removed: code)] [added: code)] |
[removed: Securities] [added: Securities] registered pursuant to Section 12(b) of the [removed: Act:][added: Act:]
| [removed: Title] [added: Title] of each [removed: class] [added: class] | [removed: Trading Symbol(s)] [added: Trading Symbol(s)] | [removed: Name] [added: Name] of each exchange on which [removed: registered] [added: registered] |
[removed: Securities] [added: Securities] registered pursuant to Section 12(g) of the Act: [removed: None][added: None]
| Large accelerated filer | [removed: |] ☒ | [removed: |] Accelerated filer | [removed: |] ☐ |
| Non-accelerated filer | [removed: |] ☐ | [removed: |] Smaller reporting company | [removed: |] ☐ |
| | | [removed: | |] Emerging growth company | [removed: |] ☐ |
As of December 31, [removed: 2018] [added: 2025,] the aggregate market value of the Common Stock held by non-affiliates of the Registrant was [removed: $5.5] [added: $9.1] billion based upon the closing sale price as reported on The Nasdaq Stock Market [removed: ($144.72] [added: ($58.81] per share).
As of [removed: August 26, 2019, 38,063,504] [added: October 9, 2026, 157,055,564] shares of the Company’s Common Stock ($0.01 par value) were outstanding.
[removed: EXPLANATORY NOTE][added: EXPLANATORY NOTE]
[removed: TABLE] [added: TABLE] OF [removed: CONTENTS][added: CONTENTS]
| [removed: Item] [added: [ITEM] 15. [removed: | [Exhibits, Financial Statement Schedules](#item15)] [added: EXHIBITS, FINANCIAL STATEMENT SCHEDULES](#ITEM15.)] | [removed: 40] [added: 45] |
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).
DOCUMENTS INCORPORATED BY REFERENCE
None.
This Amendment No. 1 on Form 10-K/A (the “Form 10-K/A”) to the Annual Report on Form 10-K of Bio-Techne Corporation (the “Company”) for the fiscal year ended June 30, 2026, filed with the Securities and Exchange Commission (the “SEC”) on August 24, 2026 (the “Original Report”), is being filed solely for the purpose of including the information required by Part III of Form 10-K that the Company did not include in the Original Report in reliance on General Instruction G(3) to Form 10-K, which permits this information to be incorporated by reference from a registrant’s definitive proxy statement if the proxy statement is filed within 120 days after fiscal year-end.
We are filing this Form 10-K/A to include Part III information in our Form 10-K because we do not intend to file a definitive proxy statement for an annual meeting of shareholders containing such information within 120 days after the end of our fiscal year ended June 30, 2026.
The reference on the cover page of the Original Report to such incorporation by reference has been deleted and the number of shares of Common Stock outstanding has been updated.
This Form 10-K/A amends and restates in their entirety Items 10 through 14 of Part III of the Original Report.
Capitalized terms not otherwise defined in Part III of this Form 10-K/A shall have the same meanings assigned to those terms in Parts I and II of the Original Report.
In addition, in connection with the filing of this Form 10-K/A and pursuant to the rules of the SEC, we are including in this Form 10-K/A new certifications of our principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are filed as Exhibits 31.3 and 31.4 to this Form 10-K/A.
Item 15 of Part IV of the Original Report is amended solely to add these certifications to the exhibit index, and the exhibit index and the exhibits filed with the Original Report are not otherwise amended or restated.
Because no financial statements are included in this Form 10-K/A and this Form 10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted.
Because no financial statements are contained in this Form 10-K/A, we are not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Except as described above, this Form 10-K/A does not modify or update the disclosures in, or any exhibits to, the Original Report.
Furthermore, this Form 10-K/A does not change any previously reported financial results, nor does it reflect any events which occurred subsequent to the filing of the Original Report.
Information not affected by this Form 10-K/A remains unchanged and reflects the disclosures made at the time the Original Report was filed.
Unless otherwise specified or indicated by the context, “Bio-Techne,” the “Company,” “we,” “us” and “our” refer to Bio-Techne, its divisions and subsidiaries.
| [PART III](#PARTIII) | 5 |
| [ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE](#ITEM10.) | 5 |
| [ITEM 11. EXECUTIVE COMPENSATION](#ITEM11.) | 13 |
| [ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS](#ITEM12.) | 39 |
| [ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE](#ITEM13.) | 43 |
| [ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES](#ITEM14.) | 44 |
| [PART IV](#PARTIV) | 45 |
[*Table of Contents*](#TABLEOFCONTENTS)
PART III
| ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE |
EXECUTIVE OFFICERS
Information regarding our executive officers is set forth under the “Executive Officers of the Registrant” caption in Part I, Item 1 of the Original Report, which is hereby incorporated by reference.
DIRECTORS
The following sets forth information concerning the directors serving on the Board of Directors (the “Board”) of the Company.
Director Qualifications and Experience
[*Table of Contents*](#TABLEOFCONTENTS)
| | Skills, Qualifications, and Background | |  |  |  |  |  |  |  |  |  | |
| |  | Executive/Strategic Leadership |  |  | |  |  |  |  |  |  |  |
| | Senior-level managerial experience brings a broad perspective and knowledge to engage with management in meaningful discussions about our strategy and related strategic risks, including people management. | | | | | | | | | | | |
| |  | Industry Background | | |  |  |  |  |  |  |  |  |
| | The life science tools and diagnostics industry is complex and technology-focused, so having directors with experience in this business, either as executives or customers, is a significant advantage. | | | | | | | | | | | |
| |  | Scientific/Technical | | |  | |  |  |  |  |  |  |
10-K/A 1 tech20190923_10ka.htm FORM 10-K/A
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
This Amendment No. 1 on Form 10-K/A (“Amendment No. 1”) amends Bio-Techne Corporation’s (the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2019, as filed with the Securities and Exchange Commission (“SEC”) on August 28, 2019 (the “Original Filing”), solely to provide a revised version of KPMG LLP’s (“KPMG”) report, which corrects certain clerical items and a statement in the previously filed version that KPMG did not express an opinion on the Company’s internal controls over financial reporting, and makes a clerical correction in Item 9A to conform the name of the entity the Company acquired on June 4, 2019 to the Company’s consolidated financial statements.
These changes to the filed version of KPMG's report included in the original filing do not affect KPMG's unqualified opinion on the Company's consolidated financial statements or KPMG's unqualified opinion on internal control over financial reporting included in the Original Filing and this Amendment No. 1.
As required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 includes a new consent of KPMG (Exhibit 23.1), new certifications from the Company's principal executive officer (Exhibit 31.1) and principal financial officer (Exhibit 31.2) and new Section 1350 certifications (Exhibit 32.1 and 32.2) dated as of the date of filing of this Amendment No. 1.
This Amendment No. 1 consists solely of the preceding cover page, this explanatory note, Part II., Item 8., “Consolidated Financial Statements and Supplementary Data,” in its entirety, Part IV., Item 15., “Exhibits and Financial Statement Schedules,” in its entirety, the signature page, and the new certifications from the Company’s principal executive officer and principal financial officer.
Except as expressly set forth above, this Amendment does not, and does not purport to, amend, update or restate the information in any other item of the Original Filing.
Amendment No. 1 speaks as of the date of the Original Filing, does not reflect events that may have occurred after the date of the Original Filing and does not modify or update in any way the disclosures made in the Original Filing, except as described above.
Amendment No. 1 should be read in conjunction with the Original Filing and with the Company’s subsequent filings with the SEC.
| Item 8. | [Financial Statements and Supplementary Data](#item8) | 1 |
| Item 9. | [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](#item9) | 38 |
| Item 9A. | [Controls and Procedures](#item9a) | 38 |
| | [SIGNATURES](#signatures) | 42 |
An excerpt. Shown here: all 27 rewritten, 40 of 755 added and all 13 removed. The counts are complete. For every sentence, read Cover and table of contents in the FY2026 filing and the FY2019 filing.
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS
0 rewritten, 65 added, 0 removed, 0 unchanged
New section this year
Read the full itemFY2026 item · filed October 28, 2026
EQUITY COMPENSATION PLAN INFORMATION
We currently award stock-based compensation, including stock options and restricted stock units, under the 2020 Equity Incentive Plan.
The following table presents information about common stock authorized for issuance under that plan as of June 30, 2026:
| | Plan Category | | Number of Securities to be Issued Upon Exercise of Outstanding Options (# in 000’s) | | | | Weighted Avg. Exercise Price of Outstanding Options ($) | | | | Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (A)) (# in 000’s) | | |
| | | | (A) | | | | (B) | | | | (C) | | |
| | Equity compensation plans approved by shareholders | | | 6,991 | | | $ | 73.47 | | | | 5,876 | |
| | Equity compensation plans not approved by shareholders | | | \- | | | | N/A | | | | \- | |
| | Total | | | 6,991 | | | | 73.47 | | | | 5,876 | |
As of October 9, 2026, there were 5,242,909 shares available for future grants under the 2020 Equity Incentive Plan, and the closing price per share of our common stock was $72.46 as reported on The Nasdaq Global Select Market.
[*Table of Contents*](#TABLEOFCONTENTS)
Principal Shareholders
The following table provides information concerning the only persons known to the Company to be the beneficial owners of more than 5% of the Company’s outstanding common stock as of October 9, 2026.
| | Name and Address of Beneficial Owner | | Amount and Nature of Shares Beneficially Owned | | | | | Percent of Class | | |
| | Vanguard Capital Management | | | | | | | | | |
| | | | | 11,559,571 | (1) | | | | 7.4 | % |
| | BlackRock, Inc. | | | | | | | | | |
| | | | | 11,011,556 | (2) | | | | 7.0 | % |
| | FMR LLC | | | | | | | | | |
| | | | | 12,754,784 | (3) | | | | 8.1 | % |
| (1) | Based solely on information contained in a Schedule 13G, filed with the SEC on April 29, 2026, by Vanguard Capital Management (“VCM”), in which VCM reported that, as of March 31, 2026, it had sole voting power as to 1,379,862 shares of Bio-Techne Common Stock and sole dispositive power as to 11,559,571 shares of Bio-Techne Common Stock. The address of VCM is 100 Vanguard Boulevard, Malvern, Pennsylvania 19355. |
| (2) | Based solely on information contained in a Schedule 13G/A, filed with the SEC on July 16, 2025, by BlackRock, Inc. (“BlackRock”), in which BlackRock reported that, as of June 30, 2025, it had sole voting power as to 10,333,812 shares of Bio-Techne Common Stock and sole dispositive power as to 11,011,556 shares of Bio-Techne Common Stock. The address of BlackRock is 50 Hudson Yards, New York, New York 10001. |
| (3) | Based solely on information contained in a Schedule 13G/A, filed with the SEC on August 6, 2026, by FMR LLC (“FMR”), in which FMR reported that, as of June 30, 2026, it had sole voting power as to 12,715,889.05 shares of Bio-Techne Common Stock and sole dispositive power as to 12,754,783.64 shares of Bio-Techne Common Stock. The address of FMR is 245 Summer Street, Boston, Massachusetts 02210. |
[*Table of Contents*](#TABLEOFCONTENTS)
Management Shareholdings
The following table sets forth the number of shares of the Company’s common stock beneficially owned as of October 9, 2026, by each named executive officer, by each director, and by all directors and current executive officers as a group.
Each individually beneficially owns less than one percent of total shares outstanding, which includes shares subject to options such individual may exercise.
As a group, executive officers and directors beneficially own 1.3% of total shares outstanding.
| | Name of Director or Executive Officer | Number of Shares Beneficially Owned(1) | | % Owned | |
| | Robert V. Baumgartner | 108,265 | (2) | * | * |
| | Joseph Keegan, Ph.D. | 66,792 | (3) | * | * |
| | John L. Higgins | 128,635 | (4) | * | * |
| | Alpna Seth, Ph.D. | 46,700 | (5) | * | * |
| | Dr. Rupert Vessey, MA, BM BCh, FRCP, DPhil | 44,628 | (6) | * | * |
| | Julie L. Bushman | 33,464 | (7) | * | * |
| | Dr. Judith Klimovsky | 12,680 | (8) | * | * |
| | Dr. Amy Herr | 20,417 | (9) | * | * |
| | Kim Kelderman | 390,300 | (10) | * | * |
| | James Hippel | 497,202 | (11) | * | * |
| | William Geist | 111,317 | (12) | * | * |
| | Shane Bohnen | 53,470 | (13) | * | * |
An excerpt. Shown here: all 0 rewritten, 40 of 65 added and all 0 removed. The counts are complete. For every sentence, read Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS in the FY2026 filing.
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
0 rewritten, 51 added, 0 removed, 0 unchanged
New section this year
Read the full itemFY2026 item · filed October 28, 2026
Related Party Transactions
As provided in its charter, the Nominations and Governance Committee reviews and approves all related party transactions involving the Company’s directors and executive officers or their immediate family members to determine whether such transactions meet applicable legal requirements and are appropriately disclosed.
The Company has adopted a written policy concerning the review of related party transactions, which provides that, in determining whether to approve or ratify a related party transaction, the Nominations and Governance Committee will take into account, among other factors it deems appropriate, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person’s interest in the transaction.
In addition, the Company’s Code of Ethics and Business Conduct requires all directors and executive officers to inform the Company’s legal counsel of any existing or proposed relationship or business transaction that could be, or might appear to be, a conflict of interest.
Any reported transactions would be brought to the attention of the Nominations and Governance Committee for review and disposition.
Since the beginning of the last fiscal year, there have been no related party transactions requiring disclosure under applicable rules and regulations.
Board Independence
Bio-Techne’s Principles of Corporate Governance provide that a majority of the Board must be independent directors under criteria established by the Board in conformity with the listing rules of the Nasdaq Stock Market.
The Nominations and Governance Committee annually reviews the independence of each director, including whether there are any related party transactions.
In making its most recent independence determinations, the Nominations and Governance Committee reviewed transactions and relationships between each director or any member of a director’s immediate family on one side, and the Company or any of its subsidiaries on the other side, based on information provided by the directors and from Company records and publicly available information.
The Committee determined and the Board confirmed that all of the Company’s non-employee directors are independent.
When Dr. Herr was appointed to the Board in fiscal year 2025, the Company noted that her partner was an employee (a non-executive officer) of a Bio-Techne subsidiary whose compensation from the Company was strictly in connection with his employment.
In conjunction with Dr. Herr’s selection and formal appointment, the Board determined that this relationship, including her partner’s level and role within the Company’s subsidiary, would not undermine her ability to make decisions as a director.
Accordingly, the Board determined Dr. Herr to be an independent director, and implemented additional compliance safeguards to assist Dr. Herr and her partner in maintaining her independent status.
[*Table of Contents*](#TABLEOFCONTENTS)
| ITEM 14. | PRINCIPAL ACCOUNTANT FEES AND SERVICES |
Audit Fees
The following fees were paid or payable to KPMG LLP for the fiscal years ended June 30, 2026 and 2025 (in thousands):
| | | | 2025 ($) | | | | 2026 ($) | | |
| | Audit Fees | | $ | 2,377 | | | $ | 2,447 | |
| | Audit-Related Fees | | | 110 | | | | 110 | |
| | Tax Fees | | | 254 | | | | 123 | |
| | All Other Fees | | | \- | | | | \- | |
“Audit Fees” are for professional services rendered and expenses incurred for the audit of the Company’s annual financial statements and review of financial statements included in our Forms 10-K and 10-Q or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements.
Audit Fees also included fees incurred for the audit of the effectiveness of our internal controls over financial reporting.
“Audit-Related Fees” are mainly for agreed-upon procedures (agreed-upon or expanded audit procedures related to accounting records required to respond to or comply with financial, accounting, or regulatory matters).
Audit-Related Fees for fiscal year 2025 included $100,000 for ESG reporting readiness services relating to fiscal years 2024 and 2025.
“Tax Fees” for fiscal year 2026 included $123,000 for domestic and international tax return preparation services and tax compliance and consulting services.
“Tax Fees” for fiscal year 2025 included fees for services provided and expenses incurred in connection with (i) preparation of the Company’s tax returns in the United States, Germany, and the United Kingdom and inquiries and audits related to such returns, $118,000; and (ii) tax consulting, $136,000.
[*Table of Contents*](#TABLEOFCONTENTS)
Pre-Approval Policies and Procedures
Pursuant to its written charter, the Audit Committee is required to pre-approve the audit and non-audit services performed by the Company’s independent registered public accounting firm.
The Audit Committee may delegate to one or more of its members the authority to grant pre-approvals so long as such pre-approvals are reported to and reviewed by the full Committee at its next meeting.
Annual tax services are reviewed and approved by the Audit Committee prior to the commencement of such services.
All of the services rendered by KPMG LLP in fiscal years 2026 and 2025 were pre-approved by the Audit Committee.
PART IV
| ITEM 15. | EXHIBITS, FINANCIAL STATEMENT SCHEDULES |
Item 15 of Part IV of the Original Report is hereby amended solely to add the exhibits listed below.
No financial statements or financial statement schedules are filed with this Form 10-K/A, and the exhibit index included in the Original Report is not otherwise amended or restated.
Exhibit Index
An excerpt. Shown here: all 0 rewritten, 40 of 51 added and all 0 removed. The counts are complete. For every sentence, read Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE in the FY2026 filing.
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
0 rewritten, 0 added, 1,181 removed, 0 unchanged
Dropped this year
Read the full itemFY2019 item · filed October 9, 2019
CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME
_Bio-Techne Corporation and Subsidiaries
(in thousands, except per share data)_
| | | __Year Ended June 30,__ | | | | | | | | | | |
| | | __201__9__ | | | | __201__8__ | | | | __201__7__ | | |
| Net sales | | $ | 714,006 | | | $ | 642,993 | | | $ | 563,003 | |
| Cost of sales | | | 240,515 | | | | 210,850 | | | | 188,462 | |
| Gross margin | | | 473,491 | | | | 432,143 | | | | 374,541 | |
| Operating expenses: | | | | | | | | | | | | |
| Selling, general and administrative | | | 264,359 | | | | 240,636 | | | | 200,443 | |
| Research and development | | | 62,413 | | | | 55,329 | | | | 53,514 | |
| Total operating expenses | | | 326,772 | | | | 295,965 | | | | 253,957 | |
| Operating income | | | 146,719 | | | | 136,178 | | | | 120,584 | |
| Other income (expense): | | | | | | | | | | | | |
| Interest expense | | | (21,705 | ) | | | (10,188 | ) | | | (7,361 | ) |
| Interest income | | | 569 | | | | 409 | | | | 304 | |
| Other non-operating income (expense), net | | | (13,568 | ) | | | (447 | ) | | | (1,566 | ) |
| Total other income (expense), net | | | (34,704 | ) | | | (10,226 | ) | | | (8,623 | ) |
| Earnings before income taxes | | | 112,015 | | | | 125,952 | | | | 111,961 | |
| Income taxes (benefit) | | | 15,943 | | | | (198) | | | | 35,875 | |
| Net earnings | | | 96,072 | | | | 126,150 | | | | 76,086 | |
| Other comprehensive income (loss): | | | | | | | | | | | | |
| Foreign currency translation adjustments | | | (4,487 | ) | | | (1,572 | ) | | | (3,061 | ) |
| Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax of $2,921 in FY19 | | | (9,537 | ) | | | \- | | | | \- | |
| Unrealized gains (losses) on available-for-sale investments, net of tax of $398 in FY18 and $(6,501) in FY17 | | | \- | | | | 5,693 | | | | 24,531 | |
| Other comprehensive income (loss) | | | (14,024 | ) | | | 4,121 | | | | 21,470 | |
| Comprehensive income | | $ | 82,048 | | | | 130,271 | | | $ | 97,556 | |
| Earnings per share: | | | | | | | | | | | | |
| Basic | | $ | 2.54 | | | $ | 3.36 | | | $ | 2.04 | |
| Diluted | | $ | 2.47 | | | $ | 3.31 | | | $ | 2.03 | |
| Weighted average common shares outstanding: | | | | | | | | | | | | |
| Basic | | | 37,781 | | | | 37,476 | | | | 37,313 | |
| Diluted | | | 38,892 | | | | 38,055 | | | | 37,500 | |
See Notes to Consolidated Financial Statements.
CONSOLIDATED BALANCE SHEETS
_Bio-Techne Corporation and Subsidiaries
(in thousands, except share and per share data)_
| | | __June 30,__ | | | | | | |
| | | __201__9__ | | | | __201__8__ | | |
| ASSETS | | | | | | | | |
An excerpt. Shown here: all 0 rewritten, all 0 added and 40 of 1,181 removed. The counts are complete. For every sentence, read Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA in the FY2019 filing.
Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
0 rewritten, 0 added, 1 removed, 0 unchanged
Dropped this year
Read the full itemFY2019 item · filed October 9, 2019
None.
Item 9A. CONTROLS AND PROCEDURES
0 rewritten, 0 added, 29 removed, 0 unchanged
Dropped this year
Read the full itemFY2019 item · filed October 9, 2019
| (a) | Evaluation of Disclosure Controls and Procedures |
As required by Rule 13a-15(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this report, the effectiveness of our disclosure controls and procedures as defined in Exchange Act Rule 13a-15(e).
The evaluation was based upon reports and certifications provided by a number of executives.
Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2019, our disclosure controls and procedures were effective.
| (b) | Management's Annual Report on Internal Control Over Financial Reporting |
The Company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
A company's internal control over financial reporting also includes those policies and procedures that:
| (i) | Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; |
| (ii) | Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and |
| (iii) | Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's assets that could have a material effect on the financial statements. |
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.
We acquired QT Holding Corporation (Quad) on July 2, 2018, Exosome Diagnostics Inc. (Exosome) on August 1, 2018, and B-MoGen Biotechnologies Inc. (B-Mogen) on June 4, 2019.
Quad, Exosome, and B-Mogen represented approximately 17.2% of our total assets and 0.5% of our total revenues as of and for the year ended June 30, 2019.
We excluded internal control over financial reporting associated with Quad, Exosome, and B-Mogen from our assessment of the effectiveness of our internal control over financial reporting as of June 30, 2019.
Under the supervision of the Audit Committee of the Board of Directors and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria established in _Internal Control - Integrated Framework (2013)_ issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
Based on our assessment and those criteria, our Chief Executive Officer and Chief Financial Officer concluded that our internal control over financial reporting was effective as of June 30, 2019.
The attestation report on our internal control over financial reporting issued by KPMG LLP appears in Item 8 of this report.
| (c) | Changes in Internal Control Over Financial Reporting |
As previously announced, we acquired Quad on July 2, 2018, Exosome on August 1, 2018, and B-Mogen on June 4, 2019.
We have not fully evaluated any changes in internal control over financial reporting associated with these acquisitions and therefore any material changes that may result from these acquisitions have not been disclosed in this report.
We intend to disclose all material changes resulting from these acquisitions within or prior to the time of our first annual assessment of internal control over financial reporting that is required to include these entities.
We acquired Trevigen Inc (Trevigen) on September 5, 2017, Atlanta Biologicals (Atlanta) on January 2, 2018, and Eurocell Diagnostics SAS (Eurocell) on February 1, 2018, and we have implemented our internal control structure over these and incorporated its operations into our assessment of internal control over financial reporting as of June 30, 2019.
We have extended our oversight and monitoring processes that support internal control over financial reporting to include the operations of these entities.
There were no other changes in the Company's internal control over financial reporting during fiscal year 2019 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.
PART IV
Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
0 rewritten, 0 added, 77 removed, 0 unchanged
Dropped this year
Read the full itemFY2019 item · filed October 9, 2019
A.
(1) List of Financial Statements.
The following Consolidated Financial Statements are filed as part of this Annual Report on Form 10-K:
Consolidated Statements of Earnings and Comprehensive Income for the Years Ended June 30, 2019, 2018, and 2017
Consolidated Balance Sheets as of June 30, 2019 and 2018
Consolidated Statements of Shareholders' Equity for the Years Ended June 30, 2019, 2018, and 2017
Consolidated Statements of Cash Flows for the Years Ended June 30, 2019, 2018, and 2017
Notes to Consolidated Financial Statements for the Years Ended June 30, 2019, 2018, and 2017
Reports of Independent Registered Public Accounting Firm
A.
(2) Financial Statement Schedules.
All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the Consolidated Financial Statements or Notes thereto.
A.
(3) Exhibits.
EXHIBIT INDEX
for Form 10-K for the 2019 Fiscal Year
| Exhibit Number | Description |
| 3.1 | [Amended and Restated Articles of Incorporation of the Company--incorporated by reference to Exhibit 3.1 of the Company's Form 10-Q dated February 9, 2015*](http://www.sec.gov/Archives/edgar/data/842023/000143774915002131/ex3-1.htm) |
| 3.2 | [Third Amended and Restated Bylaws of the Company--incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K dated February 1, 2018*](http://www.sec.gov/Archives/edgar/data/842023/000143774918001755/ex_104373.htm) |
| 10.1 | [Management Incentive Plan--incorporated by reference to Exhibit 10.13 of the Company's Form 10-K for the year ended June 30, 2013*](http://www.sec.gov/Archives/edgar/data/842023/000119312513351961/d545574dex1013.htm) |
| 10.2 | [Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.1 of the Company's Form 8-K dated October 26, 2017*](http://www.sec.gov/Archives/edgar/data/842023/000143774917017673/ex_97613.htm) |
| 10.3 | [Form of Restricted Stock Award Agreement for Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.6 of the Company's Form 8-K dated October 26, 2017*](http://www.sec.gov/Archives/edgar/data/842023/000143774917017673/ex_97618.htm) |
| 10.4 | [Form of Restricted Stock Unit Award Agreement for Second Amended and Restated 2010 Equity Incentive Plan attached as Exhibit 10.4 hereto](http://www.sec.gov/Archives/edgar/data/842023/000143774919017565/ex_156203.htm) |
| 10.5 | [Form of the Performance Unit Award Agreement for Second Amended and Restated 2010 Equity Incentive Plan attached as Exhibit 10.5 hereto](http://www.sec.gov/Archives/edgar/data/842023/000143774919017565/ex_156204.htm) |
| 10.6 | [Form of Incentive Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan--attached as Exhibit 10.6 hereto.](http://www.sec.gov/Archives/edgar/data/842023/000143774919017565/ex_156205.htm) |
| 10.7 | [Form of Employee Non-Qualified Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan--attached as Exhibit 10.7 hereto.](http://www.sec.gov/Archives/edgar/data/842023/000143774919017565/ex_156206.htm) |
| 10.8 | [Form of Director Non-Qualified Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.2 of the Company's Form 8-K dated October 26, 2017*](http://www.sec.gov/Archives/edgar/data/842023/000143774917017673/ex_97614.htm) |
| 10.9 | [Employment Agreement by and between the Company and Charles Kummeth--incorporated by reference to Exhibit 10.11 of the Company's Form 10-K dated September 7, 2017*](http://www.sec.gov/Archives/edgar/data/842023/000143774917015711/ex10-11.htm) |
| Exhibit Number | Description |
| 10.10 | [Form of Employment Agreement by and between the Company and Executive Officers of the Company other than the CEO--incorporated by reference to Exhibit 10.12 of the Company's Form 10-K dated September 7, 2017*](http://www.sec.gov/Archives/edgar/data/842023/000143774917015711/ex10-12.htm) |
| 10.11 | [Credit Agreement by and among the Company, the Guarantors party thereto, the Lenders party thereto, and BMO Harris Bank N.A., as Administrative Agent, dated August 1, 2018--incorporated by reference to Exhibit 10.1 of the Company's Form 8-K dated August 2, 2018*](http://www.sec.gov/Archives/edgar/data/842023/000143774918014310/ex_119784.htm) |
| 10.12 | [Form of Indemnification Agreement entered into with each director and executive officer of the Company--incorporated by reference to Exhibit 10.1 of the Company's Form 10-Q dated February 8, 2018*](http://www.sec.gov/Archives/edgar/data/842023/000143774918001995/ex_104397.htm) |
| 10.13 | [Agreement and Plan of Merger by and among the Company, Aero Merger Sub Inc., Advanced Cell Diagnostics, Inc. and Fortis Advisors, LLC as the Securityholders’ Representative, dated July 6, 2016--incorporated by reference to Exhibit 2.1 of the Company's Form 8-K dated July 7, 2016*](http://www.sec.gov/Archives/edgar/data/842023/000143774916034990/ex2-1.htm) |
| 10.14 | [Agreement and Plan of Merger between the Company, Enzo Merger Sub. Inc., Exosome Diagnostics, Inc. and The Securityholders Representative, dated July 25, 2018--incorporated by reference to Exhibit 2.1 of the Company's Form 8-K dated June 25, 2018*](http://www.sec.gov/Archives/edgar/data/842023/000143774918012358/ex_116925.htm) |
| 21 | [Subsidiaries of the Company](http://www.sec.gov/Archives/edgar/data/842023/000143774919017565/ex_156245.htm) |
| 23 | [Consent of KPMG LLP, Independent Registered Public Accounting Firm](https://www.sec.gov/Archives/edgar/data/842023/000143774919019836/ex_159279.htm) |
| 31.1 | [Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](https://www.sec.gov/Archives/edgar/data/842023/000143774919019836/ex_158474.htm) |
| 31.2 | [Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](https://www.sec.gov/Archives/edgar/data/842023/000143774919019836/ex_158475.htm) |
| 32.1 | [Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](https://www.sec.gov/Archives/edgar/data/842023/000143774919019836/ex_158476.htm) |
| 32.2 | [Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](https://www.sec.gov/Archives/edgar/data/842023/000143774919019836/ex_158477.htm) |
An excerpt. Shown here: all 0 rewritten, all 0 added and 40 of 77 removed. The counts are complete. For every sentence, read Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES in the FY2019 filing.